October 24, 2013 — Transcatheter Technologies GmbH, a medical device company, announced the successful first-in-human implantation of its transapical Trinity aortic valve.
“A major limitation of existing transcatheter aortic heart valves is that they cannot be repositioned once implanted. Trinity, however, is designed to solve this difficult problem,” said Wolfgang Goetz, M.D., Ph.D., CEO, Transcatheter Technologies. “With Trinity, once our valve is initially placed, a cardiologist can fully evaluate the valve’s function to determine whether it needs to be repositioned, retrieved or kept in the same position. Equally important, Trinity provides for a controlled positioning by allowing a cardiologist to slowly open the valve stent, thus improving the likelihood of a first-attempt correct placement.”
“The Trinity aortic valve can be positioned precisely. Yet, it also allows for safe repositioning of the valve prosthesis — or even full retrieval — if necessary. Its unique sealing cuff provides excellent results without paravalvular leakage. Moreover, the risk for atrio-ventricular block is dramatically reduced due to the supraannular positioning of Trinity,” said Dr. Christian Hengstenberg, cardiologist, German Heart Centre, Munich, Germany.
The results of the first-in-human clinical trial using Trinity will be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting on Oct. 28, 2013 in San Francisco.
For more information: www.transcathetertechnologies.com
November 18, 2024 
